Effects of ivabradine on patients with depressed left ventricular ejection fraction after cardiac resynchronization therapy

25 May 2019 (00:00 - 00:00)

Organised by:

Sign in to view the resources

About the speaker

Doctor Chao-Wen Hsieh

Cheng-Hsin General Hospital, Taipei (Taiwan)

56 More presentations in this session

Presentation thumbnail

Effects of mineralocorticoid ceceptor antagonists (MRA) in heart failure patients after up to 12 months of follow-up.

Doctor L. Borg (Msida, MT)

Presentation thumbnail

Sacubitril valsartan, a multicentric experience

Mr F. Cortes (Sevilla, ES)

Presentation thumbnail

Reduction of NT-proBNP in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction in short-term treatment with empagliflozin on top of existing therapy

Professor B. Kanazirev (Varna, BG)

Abstract Slides

Presentation thumbnail

Effects of sacubitril/valsartan on real-world patients with heart failure due to non-ischemic cardiomyopathy

Associate Professor C. Hsu (Taipei, TW)

Abstract Slides

Presentation thumbnail

Benefits of early administration of ivabradine in stabilized patients hospitalized due to worsening heart failure: insights from the Optimize Heart Failure Care Program

Doctor L. Mircheva (Varna, BG)

Access the full session

Session thumbnail

Poster Session 3 - Chronic Heart Failure – Treatment

The Event

Heart Failure 2019

25 May - 28 May 2019

You may be interested in

Congress Presentation

Breaking the barriers in guideline-directed medical therapy implementation in heart failure - discussion

Congress Presentation

The role of ICD therapy in heart failure in 2024. What is the holistic approach to treat heart failure?

Congress Session

Guideline-directed medical therapy implementation in special clinical scenarios

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources